Scarica l'app Stockscreener
19.14
9.59%
-2.03
Pre-mercato:
19.39
0.25
+1.31%
Spyre Therapeutics Inc Borsa (SYRE) Ultime notizie
Best data tools to analyze Spyre Therapeutics Inc. stockMarket Growth Report & Stepwise Entry/Exit Trade Alerts - newser.com
What sentiment indicators say about Spyre Therapeutics Inc. stock2025 Performance Recap & Entry Point Strategy Guides - newser.com
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 5%Here's Why - MarketBeat
Why Spyre Therapeutics Inc. stock is a value investor pickWeekly Profit Report & AI Powered Market Trend Analysis - newser.com
Analyzing Spyre Therapeutics Inc. with risk reward ratio charts2025 Trading Recap & Stock Portfolio Risk Control - newser.com
How to integrate Spyre Therapeutics Inc. into portfolio analysis toolsJuly 2025 Institutional & Accurate Technical Buy Alerts - newser.com
Is Spyre Therapeutics Inc. a candidate for recovery playWeekly Trend Summary & Community Trade Idea Sharing Platform - newser.com
Custom strategy builders for tracking Spyre Therapeutics Inc.July 2025 Opening Moves & Low Risk Investment Opportunities - newser.com
Spyre Therapeutics' (SYRE) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Shares Up 8.9%What's Next? - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Published on: 2025-10-06 01:19:10 - newser.com
Spyre Therapeutics (SYRE) Highlights Progress at European Gastro - GuruFocus
Spyre Therapeutics Presents Promising Phase 1 Data for SPY002 at UEGW Congress - Quiver Quantitative
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025 - The Manila Times
6-Month Data: Spyre's SPY002 Shows Q3M Dosing Potential; Preclinical Combos Superior - Stock Titan
Spyre Therapeutics Inc. stock volume spike explainedWeekly Investment Summary & Real-Time Market Sentiment Reports - newser.com
Tools to monitor Spyre Therapeutics Inc. recovery probability2025 Stock Rankings & Smart Money Movement Tracker - newser.com
Spyre Therapeutics Inc. stock daily chart insightsEarnings Performance Report & Safe Capital Growth Trade Ideas - newser.com
Is Spyre Therapeutics Inc. (3920) stock inflation resilientMarket Risk Analysis & AI Driven Price Predictions - newser.com
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
42,500 Stock Options — Spyre Therapeutics Grants Options at $16.46 to Three Non‑Executive Employees - Stock Titan
What Fibonacci levels say about Spyre Therapeutics Inc. reboundJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - newser.com
Will Spyre Therapeutics Inc. stock pay special dividends2025 Macro Impact & Real-Time Volume Analysis - newser.com
What candlestick patterns are forming on Spyre Therapeutics Inc.Trend Reversal & Weekly High Conviction Ideas - newser.com
Why millennials buy Spyre Therapeutics Inc. (3920) stockTrade Risk Report & Smart Swing Trading Techniques - newser.com
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $54.29 Average PT from Brokerages - Defense World
What analysts say about Spyre Therapeutics Inc 3920 stockStock Watchlist Updates & Low Risk Capital Growth - earlytimes.in
What technical charts say about Spyre Therapeutics Inc. stockJuly 2025 Snapshot & Daily Profit Focused Screening - newser.com
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Published on: 2025-09-29 23:52:21 - newser.com
Published on: 2025-09-29 23:49:14 - newser.com
Published on: 2025-09-29 13:35:29 - newser.com
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):